Proactive Investors - Run By Investors For Investors

Puretech Health hails US approval of weight loss aid Plenity

Plenity has been cleared for the BMI 25-40 kg/M2 category, the widest category of adults suffering from obesity
PLENITY users shed 3.5 inches from their waists within 6 months as part of a weight reduction programme
London-listed Puretech Health PLC (LON:PRTC) hailed the first US approval for a drug it helped to develop.
Gelesis, which is 20.5% owned by Puretech, received the go-ahead for weight reduction aid Plenity earlier than expected and with a much wider marketing label.
Plenity has been cleared for the BMI 25-40 kg/M2 category, the widest category of adults suffering from obesity.
The orally-delivered treatment will now be available alongside diet and exercise to millions of overweight people who previously would not have had a prescribed treatment, said Puretech.
Broker Peel Hunt added the wide label roughly doubles the addressable market it had expected and has raised its target price for Puretech shares to 344p from 320p.
Puretech specialises in microbiome-derived treatments and conceived and developed the platform technology behind Plenity.
Shares rose 7% to 175p.
View full PRTC profile View Profile

PureTech Health Timeline

January 22 2016

Related Articles

picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
May 09 2019
Here we take a look under the hood of Shield Therapeutics

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use